Chronic wounds affect millions globally, yet current treatments often fail because they address symptoms rather than the underlying biochemical imbalances that prevent proper tissue regeneration. This limitation has profound implications for diabetics, elderly patients, and others whose wounds resist conventional healing approaches.
Singapore researchers have engineered a tri-enzyme delivery platform that simultaneously targets multiple enzymatic pathways disrupted in non-healing wounds. The system combines three specific enzymes in a controlled-release matrix, designed to restore the precise biochemical environment necessary for tissue repair. Unlike single-target therapies, this multi-enzyme approach addresses the complex cascade of molecular events that must occur in proper sequence for wound closure.
This represents a sophisticated evolution in wound care, moving beyond passive dressings toward active biochemical intervention. The tri-enzyme strategy acknowledges that wound healing requires coordinated cellular activities—inflammation resolution, matrix remodeling, and angiogenesis—each dependent on specific enzymatic functions. Previous attempts at enzyme therapy often failed due to rapid degradation or inability to maintain therapeutic concentrations at the wound site.
While promising, this platform faces typical translation challenges: manufacturing consistency, stability during storage, and demonstrating superiority over existing treatments in large clinical populations. The approach appears most relevant for chronic wounds where natural healing mechanisms have failed, rather than acute injuries. Success would validate the principle that complex biological problems require equally sophisticated therapeutic solutions, potentially opening new avenues for enzyme-based regenerative medicine beyond wound care.